ChromaDex(US:CDXC)2025-03-05 01:54Financial Performance - Q4 2024 - Total company net sales reached $29.1 million, a 37% year-over-year increase[11] - Tru Niagen® net sales amounted to $22.7 million, representing a 29% year-over-year growth[11] - Niagen® ingredient sales experienced substantial growth, reaching $5.3 million, a 96% year-over-year increase[11] - Gross margin improved to 62.5%, a 150 basis points increase compared to the previous year[11] - Net income significantly increased to $7.2 million, a $7.1 million increase year-over-year[11] - Adjusted EBITDA nearly tripled, reaching $3.4 million compared to $1.2 million in Q4 2023[11] Financial Performance - Full Year 2024 - Total net sales grew by 19% year-over-year[11] - Net income reached $8.6 million, or $0.11 earnings per share, compared to a net loss of $4.9 million, or $0.07 loss per share in the previous year[11] - Operating cash flows amounted to $12.1 million, with a year-end cash balance of $44.7 million and no debt[11] - Adjusted EBITDA increased to $8.5 million, up from $1.9 million in FY 2023[11] 2025 Outlook - The company anticipates continued revenue growth of approximately 18% year-over-year[11]